Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

AI and Machine Learning Propel Advances in Cancer Treatment and Genetics

August 27, 2025

Innovations in artificial intelligence and machine learning are transforming oncology research and diagnostics. Landmark developments include AI models personalizing cancer treatment...

Innovations in Organ Transplantation and Preservation Technologies

August 27, 2025

Recent studies highlight advancements in organ transplantation including normothermic regional perfusion (NRP) to improve organ viability, out-of-sequence organ allocation debates focusing on...

Advancements in Medical Imaging and Diagnostic Technologies

August 27, 2025

Cutting-edge developments in medical imaging are enhancing diagnostic precision and patient monitoring. Studies report improved liver vessel segmentation algorithms for surgical planning, novel...

AbbVie’s $1.2B Bet on Psychedelic Depression Treatment

August 27, 2025

AbbVie is expanding its neuroscience portfolio with a high-stakes acquisition of Gilgamesh Pharmaceuticals’ lead psychedelic candidate bretisilocin (GM-2505) for up to $1.2 billion. Bretisilocin,...

Regeneron’s Cemdisiran Advances in Neuromuscular Disease Trials

August 27, 2025

Regeneron Pharmaceuticals announced that cemdisiran, a small interfering RNA (siRNA) licensed from Alnylam, met pivotal endpoints in Phase III trials for generalized myasthenia gravis (MG). The...

Lilly’s Oral GLP-1 Orforglipron Shows Weight Loss Efficacy in Phase III

August 27, 2025

Eli Lilly announced successful Phase III data for its oral glucagon-like peptide 1 (GLP-1) receptor agonist, orforglipron, in adults with obesity or overweight and type 2 diabetes. The trial...

Massachusetts Biotech Faces Funding and Investment Challenges

August 27, 2025

MassBio released its annual report highlighting a significant downturn in Massachusetts’ biotech sector, revealing a 17% decline in venture capital investment to $2.75 billion for H1 2025—the...

Pig-to-Human Lung Transplant Marks Xenotransplantation Milestone

August 27, 2025

Researchers achieved a pioneering xenotransplantation success by transplanting a genetically modified pig lung into a brain-dead human patient. The lung functioned for nine days without hyperacute...

FDA Suspends U.S. License for Valneva’s Chikungunya Vaccine

August 27, 2025

The FDA suspended the biologics license for Valneva's chikungunya vaccine (Ixchiq) following safety concerns, including reports of serious adverse events consistent with chikungunya-like illness...

AI and Imaging Reshape Cancer and Heart Disease Diagnostics

August 27, 2025

Artificial intelligence is making transformative impacts in clinical decision-making for oncology and cardiology. Studies show AI-based models personalizing cancer treatment protocols, including...

New Advances in Duplex Sequencing Boost Cancer Genomics

August 27, 2025

Ultima Genomics pioneered paired-plus-minus sequencing (PPM-seq), an enhanced duplex sequencing method delivering tenfold higher yield and superior accuracy in DNA variant detection. PPM-seq...

Lipid Nanoparticles Direct Dendritic Cell Immune Responses

August 27, 2025

Belgian researchers detailed how lipid nanoparticles (LNPs), foundational to mRNA vaccine platforms, dictate the maturation pathways of dendritic cells (DCs), key orchestrators of immune...

Microbial Memory Sheds Light on Antibiotic Resistance

August 27, 2025

Hebrew University researchers uncovered that bacteria retain a heritable 'memory' of environmental encounters across up to 20 generations, as revealed by Microcolony-seq technology. This discovery...

Ultima Genomics Raises Duplex Sequencing Yield Tenfold for Cancer Diagnostics

August 26, 2025

Ultima Genomics has developed a novel duplex sequencing method, paired-plus-minus sequencing (PPM-seq), boosting yield by approximately tenfold compared to existing techniques. The method achieves...

Akeso Achieves Multiple Phase III Wins in Oncology and Immunology

August 26, 2025

Chinese biotech Akeso released positive Phase III clinical trial results demonstrating significant survival benefits of its PD-1xVEGF bispecific antibody ivonescimab in non-small cell lung cancer...

Lilly's Oral GLP-1 Agonist Shows Weight Loss and Glycemic Control in Phase III

August 26, 2025

Eli Lilly’s investigational oral GLP-1 receptor agonist orforglipron demonstrated significant weight reduction and blood sugar improvements in adults with obesity or overweight and type 2...

Regeneron’s siRNA Cemdisiran Meets Phase III Endpoints in Myasthenia Gravis

August 26, 2025

Regeneron Pharmaceuticals reported successful Phase III trial results for cemdisiran, an siRNA therapeutic targeting complement factor 5, in generalized myasthenia gravis. The monotherapy...

FDA Suspends Valneva’s Chikungunya Vaccine License over Safety Concerns

August 26, 2025

The U.S. FDA has suspended the biologics license for Valneva's chikungunya vaccine, Ixchiq, following reports of serious adverse events, including hospitalizations and a death attributed to the...

AbbVie Acquires Psychedelic Drug Candidate Bretisilocin from Gilgamesh

August 26, 2025

Pharmaceutical giant AbbVie announced the acquisition of Gilgamesh Pharmaceuticals’ investigational psychedelic drug bretisilocin for up to $1.2 billion, including upfront and milestone payments....

Pioneering Pig-to-Human Lung Transplant Demonstrates Functional Viability

August 26, 2025

A landmark pig-to-human lung transplant was accomplished wherein a genetically modified pig lung, lacking hyperacute rejection markers, was transplanted into a brain-dead human patient. The organ...